25 June 2019
McCann FitzGerald advises AbbVie on its acquisition of Allergan
McCann FitzGerald is very pleased to be advising AbbVie on its acquisition of Allergan in a cash and stock transaction with a transaction equity value of approximately $63 billion.
The combination is set to create an innovative and diversified biopharmaceutical leader. AbbVie has secured fully underwritten financing commitments from Morgan Stanley Senior Funding, Inc. and MUFG Bank, Ltd., for an aggregate amount of US$38.0 billion, to finance, together with AbbVie's own cash resources, the cash portion of the acquisition. The transaction is anticipated to close by early 2020, subject to regulatory and Allergan shareholder approvals.
The McCann FitzGerald team was led by David Byers and Stephen FitzSimons (corporate) and Adrian Farrell and Philip Murphy (finance).
Select how you would like to share using the options below